Sorted By:

Relevance


Impact of the Health Insurance Marketplace on Participant Cost Sharing for Pharmacy Benefits

Access Better Coverage  |  From Our Network

This report details Milliman's analysis and the methodology used to develop these conclusions.
http://www.accessbettercoverage.org/reports/impact-of-the-health-insurance-marketplace-on-participant-cost-sharing-for-pharmacy-benefits

The Innovative Pharmaceutical Manufacturing Industry

PhRMA  |  Report

This companion report was developed with support by PhRMA to explore the economic contributions of manufacturing performed by the innovative biopharmaceutical industry versus other IP-intensive industries across a number of key measures.
https://www.phrma.org/report/the-innovative-pharmaceutical-manufacturing-industry

New Report Shows Past Drug Failures Aid in the Fight Against Cancer

PhRMA  |  Blog Post

View the full “Researching Cancer Medicines: Setbacks and Stepping Stones” report.
http://catalyst.phrma.org/new-report-shows-past-drug-failures-aid-in-the-fight-against-cancer

New PhRMA report: More than 170 medicines in development for diabetes offer patients longer, healthier lives

PhRMA  |  Blog Post

View the full report here.
http://catalyst.phrma.org/new-phrma-report-more-than-170-medicines-in-development-for-diabetes-offer-patients-longer-healthier-lives

Ask About Adherence: How poorly managed blood pressure is placing older Americans at risk for heart disease and stroke

PhRMA  |  Blog Post

Some of the report’s key findings include: Approximately 70 percent of U.S. adults age 65 and older have high blood pressure.
http://catalyst.phrma.org/ask-about-adherence-how-poorly-managed-blood-pressure-is-placing-older-americans-at-risk-for-heart-disease-and-stroke

Special Edition Medicare Monday: New report looks at Medicare negotiation proposals

PhRMA  |  Blog Post

Titled Searching for Savings in Medicare Drug Price Negotiations, here are some key points from the report:
http://catalyst.phrma.org/special-edition-medicare-monday-new-report-looks-at-medicare-negotiation-proposals

ICYMI: New Oncology Trend Report Highlights the Future Promise of Innovation

PhRMA  |  Blog Post

Here are some key highlights from the report: Innovation is occurring at a rapid pace, creating future promise for patients and their families: IMS found .imshealth.com/portal/site/imshealth/menuitem.c76283e8bf81e98f53c753c71ad8c22a/?
http://catalyst.phrma.org/icymi-new-oncology-trend-report-highlights-the-future-promise-of-innovation

New PhRMA Report: 836 medicines and vaccines in development to treat cancers

PhRMA  |  Blog Post


http://catalyst.phrma.org/new-phrma-report-836-medicines-and-vaccines-in-development-to-treat-cancers

New report: Eliminating hepatitis C today could reduce future U.S. health care spending by $115 billion over the next decade

PhRMA  |  Blog Post

Read the complete report here.
http://catalyst.phrma.org/new-report-eliminating-hepatitis-c-today-could-reduce-future-u.s.-health-care-spending-by-115-billion-over-the-next-decade

New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer

PhRMA  |  Press Release

“We released this report in Denver because of Colorado’s growing role in developing cancer medicines,” said PhRMA Senior Vice President Ken Johnson, who unveiled the report at the State Capitol Building.
https://www.phrma.org/press-release/new-report-shows-record-number-of-medicines-in-development-to-treat-leading-causes-of-cancer

Report Shows Buffalo Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases

PhRMA  |  Press Release

One potential medicine in the report could be the first to effectively treat symptoms of Huntington’s disease, an inherited, degenerative condition that destroys brain cells and is ultimately fatal.
https://www.phrma.org/press-release/report-shows-buffalo-companies-playing-key-role-in-development-of-new-medicines-for-wide-range-of-diseases

Modernizing Drug Discovery, Development & Approval

PhRMA  |  Report

Against this backdrop, pro-patient, pro-science, pro-market reforms at the Food and Drug Administration (FDA) would enhance the competitive market for biopharmaceuticals, drive efficiency in drug development and discovery and help hold down costs.
https://www.phrma.org/report/policy-solutions-modernizing-drug-discovery-development-and-approval

Medicare Monday: It is Medicare’s birthday month!

PhRMA  |  Blog Post

Tune into Medicare Monday each week for updates and new resources on all things Medicare.
http://catalyst.phrma.org/medicare-monday-it-is-medicares-birthday-month

Report Outlines Many New Medicines in Development to Battle Diabetes Epidemic Affecting More than 30 Million Americans

PhRMA  |  Press Release

The full “Medicines in Development for Diabetes” report can be downloaded here. 
https://www.phrma.org/press-release/report-outlines-many-new-medicines-in-development-to-battle-diabetes-epidemic-affecting-more-than-30-million-americans

STEM

PhRMA  |  Report

Continued scientific and technological innovations are critical to fostering sustained economic growth, global competitiveness, and most importantly, helping patients live longer, healthier, and more productive lives. The U.S. innovative biopharmaceutical industry is committed to building on new ...
https://www.phrma.org/report/stem

New Report: Nearly 4.5 Million U.S. Jobs and $1.2 Trillion Economic Output Supported by Biopharmaceutical Sector in 2014

PhRMA  |  Press Release

A U.S. fact sheet and fact sheets for all 50 states plus the District of Columbia are available online, as is the full report with detailed findings and methodology.
https://www.phrma.org/press-release/new-report-nearly-4-5-million-u-s-jobs-and-1-2-trillion-economic-output-supported-by-biopharmaceutical-sector-in-2014

List of 2016 Medicines in Development for Osteoporosis

PhRMA  |  Report

This report outlines the several medicines in development for osteoporosis including the drug name, sponsor, indication and development phase.
https://www.phrma.org/report/list-of-2016-medicines-in-development-for-osteoporosis

Medicines in Development for Older Americans 2013 Report

PhRMA  |  Report

These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 110 for diabetes, 62 for rheumatoid arthritis and osteoarthritis, 67 for Alzheimer’s disease, 61 for heart disease and 40 for chronic obstructive pulmonary disease (COPD), according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).
https://www.phrma.org

A Comparative Analysis of the Role and Impact of Health Technology Assessment

PhRMA  |  Report

However, it is also possible that a poorly designed or managed HTA process runs the risk of denying patients appropriate access to medical technologies, inefficiently allocating resources, constraining clinical freedom and sending distorted signals to medical technology providers.
https://www.phrma.org/report/a-comparative-analysis-of-the-role-and-impact-of-health-technology-assessment

Trends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B, 2006-2015

PhRMA  |  Report

Research on the pricing of prescription drugs tends to focus on individual products, rather than the overall pricing trend for the market as a whole. This larger trend—which is influenced by multiple competitive forces, including competition among products in therapeutic classes and entry o...
https://www.phrma.org/report/trends-in-weighted-average-sales-prices-for-prescription-drugs-in-medicare-part-b-2006-2015

Cost-Sharing Reductions Unevenly Applied Across Services in Exchange Plans

Access Better Coverage  |  From Our Network

Specifically, the data show broad differences in how issuers amend plan designs to meet cost- sharing requirements for those receiving cost -sharing reductions (CSR). While almost all plans reduce deductibles and out-of-pocket caps in CSR plans, many plans do not lower cost-sharing for other trea...
http://www.accessbettercoverage.org/reports/cost-sharing-reductions-unevenly-applied-across-services-in-exchange-plans

Compulsory licensing: A misused and abused international trade law

PhRMA  |  Blog Post

Compulsory licensing abuse – along with price controls and other trade barriers – threatens to chip away at our foothold and erode the resources companies can invest in the next generation of medicines.
http://catalyst.phrma.org/compulsory-licensing-a-misused-and-abused-international-trade-law

Clinical Trials: Blood Cancers

PhRMA  |  Report

There are 1,679 clinical trials listed in the National Institutes of Health database --www.clinicaltrials.gov -- for blood cancers.  Of those trials, 484 are either recruiting patients or have not yet started recruiting patients. This information is pot...
https://www.phrma.org/report/clinical-trials-blood-cancers

Policy Solutions: Engaging and Empowering Consumers

PhRMA  |  Report

Informed, engaged consumers are well equipped to judge the value of their health care. And yet, consumers too often are frustrated by hurdles that make it hard to access information about their insurance benefits and out-of-pocket health care costs. By removing some of these hurdles, we can help ...
https://www.phrma.org/report/engaging-and-empowering-consumers

New Report Shows Clinical Trials in Piedmont Triad Region Benefit Local Patients, Economy and Medical Science

PhRMA  |  Press Release

"This report highlights the potential of North Carolina's bioscience industry to provide economic opportunity and improve the quality of life of our citizens," said Atala.
https://www.phrma.org/press-release/new-report-shows-clinical-trials-in-piedmont-triad-region-benefit-local-patients-economy-and-medical-science

You have reviewed the first 200 results out of 1009. Each page contains 25 results. You're on page 8.

prev 7 8 9 10 11 12 next